Stanley T. Crooke Sells 11,000 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $52.01, for a total value of $572,110.00. Following the sale, the chairman now directly owns 48,014 shares in the company, valued at approximately $2,497,208.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) traded up $0.56 on Wednesday, hitting $51.61. 621,132 shares of the stock were exchanged, compared to its average volume of 1,034,773. The firm has a market capitalization of $6,420.00, a price-to-earnings ratio of 368.64 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. Ionis Pharmaceuticals Inc has a 1-year low of $37.26 and a 1-year high of $65.51.

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Ionis Pharmaceuticals by 4.4% in the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. BlackRock Inc. raised its position in Ionis Pharmaceuticals by 4.0% in the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after purchasing an additional 264,179 shares in the last quarter. American Century Companies Inc. raised its position in Ionis Pharmaceuticals by 33.0% in the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after purchasing an additional 284,266 shares in the last quarter. First Trust Advisors LP raised its position in Ionis Pharmaceuticals by 40.2% in the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after purchasing an additional 281,733 shares in the last quarter. Finally, Northern Trust Corp raised its position in Ionis Pharmaceuticals by 7.8% in the second quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after purchasing an additional 44,750 shares in the last quarter. 91.40% of the stock is owned by institutional investors and hedge funds.

Several analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Barclays lowered their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a report on Thursday, September 21st. BMO Capital Markets boosted their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. BidaskClub cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Finally, Zacks Investment Research cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $50.76.

COPYRIGHT VIOLATION NOTICE: This report was first reported by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://baseballnewssource.com/markets/ionis-pharmaceuticals-inc-ions-chairman-sells-572110-00-in-stock/1823830.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.